Prostate Cancer Coverage from Every Angle

Neeraj Agarwal, MD, on Clinical Implications of TITAN Trial Findings on Apalutamide Plus Androgen-Deprivation Therapy for Advanced Prostate Cancer

Posted: Saturday, March 6, 2021

Neeraj Agarwal, MD, of Huntsman Cancer Institute at the University of Utah, discusses what the final results of the TITAN study—improved overall survival and up to a 48% reduction in the risk of death, among other benefits—will mean in clinical practice for patients with metastatic castration-sensitive prostate cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.